Journal Article Summary
The article investigates the effects of glucagon-like peptide-1 receptor agonists (GLP1-RA) on weight loss and clinical outcomes in breast cancer survivors. This topic is significant because many breast cancer survivors face challenges related to obesity and type 2 diabetes, which can lead to increased health risks and complications. Understanding how GLP1-RA, a class of medications typically used for weight management and diabetes control, impacts this population could help improve their overall health and quality of life.
In this retrospective cohort study, researchers analyzed data from 1,022 breast cancer survivors who received GLP1-RA between 2005 and 2024. Most participants had type 2 diabetes, and the study focused on weight changes at three, six, and twelve months after starting the medication. The findings revealed modest weight loss, with a median change of -1.9% at three months, -3.1% at six months, and -2.6% at twelve months. Additionally, while there was no significant difference in disease-free survival (DFS) between those who used GLP1-RA and those who did not, overall survival (OS) was significantly better for GLP1-RA users.
However, the study has limitations, including its single-center design, which may affect the generalizability of the results. There is also a possibility of residual confounding and selection bias, as well as challenges in accurately measuring medication adherence. Patients and caregivers should discuss the use of GLP1-RA with healthcare professionals, especially regarding its potential benefits and risks in the context of breast cancer treatment and management of obesity and diabetes. Further clinical trials are needed to explore the long-term safety and efficacy of these medications in breast cancer survivors.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Sukumar Jasmine S., Raghavendra Akshara S., Pasyar Sarah, Bassett Roland L., Tripathy Debu, Barcenas Carlos H., Basen-Engquist Karen M., Arun Banu K.. Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors. Cancer Research Communications 2026. DOI: 10.1158/2767-9764.CRC-25-0554. PMID: 41677473. PMCID: PMC13043164.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
